Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, D. P.
Right arrow Articles by Grossbard, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, D. P.
Right arrow Articles by Grossbard, M. L.
The Oncologist, Vol. 3, No. 3, 178-188, June 1998
© 1998 AlphaMed Press


Original Papers

Pancreatic Cancer: Local Success and Distant Failure

David P. Ryan, Michael L. Grossbard

Gastrointestinal Cancer Clinic, Massachusetts General Hospital Cancer Center, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA

Correspondence: David P. Ryan, M.D., MGH Cancer Center, Cox 6, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-8515; Fax: 617-724-3166; e-mail: ryan.david{at}mgh.harvard.edu

The cure rate for pancreatic cancer remains less than 5% despite more than 20 years of clinical trials. Nevertheless, a select group of patients benefit from therapy at all stages of disease and important concepts regarding patient care have emerged. The development of agents such as gemcitabine and docetaxel have spurred a new generation of clinical trials in pancreatic cancer. An appreciation for the results of the many adjuvant and neoadjuvant trials and the application of lessons learned in the care of these patients is necessary to design the new trials.

Key Words. Pancreatic neoplasms • Combined modality therapy • Pancreaticoduodenectomy • Radiotherapy • Clinical trials • Adjuvant therapy




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Vonlaufen, S. Joshi, C. Qu, P. A. Phillips, Z. Xu, N. R. Parker, C. S. Toi, R. C. Pirola, J. S. Wilson, D. Goldstein, et al.
Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells
Cancer Res., April 1, 2008; 68(7): 2085 - 2093.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. G. El Kamar, M. L. Grossbard, and P. S. Kozuch
Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care
Oncologist, February 1, 2003; 8(1): 18 - 34.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1998 by AlphaMed Press.
Advertisement